EUVIMEDEUVIMED entdecken
Crossref

Aerosolizable Janus Protein Nanoparticles for Secondary and Tertiary Lung Cancer Chemoprevention

Albert Chang, Daren Wang, Fortune Shea, Aditya Kishan, Josh Flint, Susan R Mallery, Joerg Lahann iD

ACS Applied Bio Materials · 17.11.2026

DOI: 10.1021/acsabm.6c01387 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Bio Materials, online erschienen am 17.11.2026. Verfasst von Albert Chang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biointerfaces Institute, University of Michigan, Ann Arbor, Michigan48109, United States. Die Arbeit nennt 64 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Squamous cell carcinoma of the lung (LUSC) arises in the upper large airways of the lung. While this location appears to be readily accessible, barriers such as mucus, cilia, and resident phagocytes can limit the efficacy of inhaled chemopreventive agents. Adding to the challenges, aerosolization methods such as nebulization often induce mechanical and thermal stresses that can compromise the integrity of therapeutics and vehicles. Here, we report the aerosolization of anisotropic Janus protein nanoparticles (JNPs) prepared via electrohydrodynamic (EHD) co-jetting for co-delivery of the apolar molecule fenretinide (4HPR) and the monoclonal antibody tocilizumab (TCZ). Our findings show that JNPs experienced a marginal increase in diameter after aerosolization, from 391.3 ± 152.5 nm to 419.9 ± 168.4 nm. Scanning electron microscopy (SEM) and super-resolution confocal microscopy results confirmed minimal changes to particle morphology and preservation of the bicompartmental nature of JNPs. Furthermore, a dose-dependent study revealed that JNPs exhibit good stability in aerosols, which can be leveraged to adjust and maximize payload regardless of particle concentration. We further confirmed the retention of the therapeutics' bioactivity in vitro after aerosolization based on activation of caspase-3-mediated apoptosis and reduction of IL-6-induced STAT3-mediated signaling (via p-STAT3). Aerosolization of JNPs combines stability and preservation of biological function, and their bicompartmental design can be leveraged for further applications in co-delivery of synergistic drug combinations.

Schlagwörter

Stichwörter der Autor:innen

Janus particleaerosolizationchemopreventiveelectrohydrodynamic jettingmucoadhesiveprotein nanoparticle

Autor:innen und Institutionen

  • Biointerfaces Institute, University of Michigan, Ann Arbor, Michigan48109, United States.
  • Department of Materials Science and Engineering, University of Michigan, Ann Arbor, Michigan48109, United States.
  • Division of Oral Maxillofacial Pathology, College of Dentistry, The Ohio State University, Columbus, Ohio43210, United States.
  • Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan48109, United States.
  • Macromolecular Science and Engineering, University of Michigan, Ann Arbor, Michigan48109, United States.

ORCID-Profile: Joerg Lahann

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Chang, A., Wang, D., Shea, F., Kishan, A., Flint, J., Mallery, S. R., & Lahann, J. (2026). Aerosolizable Janus Protein Nanoparticles for Secondary and Tertiary Lung Cancer Chemoprevention. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.6c01387

Vancouver

Chang A, Wang D, Shea F, Kishan A, Flint J, Mallery SR, et al. Aerosolizable Janus Protein Nanoparticles for Secondary and Tertiary Lung Cancer Chemoprevention. ACS Applied Bio Materials. 2026. doi:10.1021/acsabm.6c01387

BibTeX
@article{Chang2026,
  author = {Chang, Albert and Wang, Daren and Shea, Fortune and Kishan, Aditya and Flint, Josh and Mallery, Susan R and Lahann, Joerg},
  title = {Aerosolizable Janus Protein Nanoparticles for Secondary and Tertiary Lung Cancer Chemoprevention},
  journal = {ACS Applied Bio Materials},
  year = {2026},
  doi = {10.1021/acsabm.6c01387}
}
Kostenlos starten →